In vitro studies, Others


Last updated: 2021 Aug 10
Total hit(s): 5
Select item(s)
Key Findings
Comments
(You can add your comments too!)
Original Article
(hover to see details)
A mammalian cell-based assay was used to identify the coronavirus 3CL protease/pro inhibitors that does not require the use of live virus which demonstrated the assays utility that were highly concordant with the results from live virus testing and identified a set of key structural features shared among broadly active 3CLpro inhibitors. The data suggested that the assay could be applicable to other protease families, thus, representing a general platform for viral protease inhibitor studies. Because of the assays breadth and ease of use, it is well suited to form the backbone of a forward-thinking pandemic preparedness strategy. This would not only be capable of addressing the current human coronaviral strains but also provide the biomedical community with a series of high-value chemical leads to perform additional focused chemical optimization. These compounds could be further checked whether they have undergone preclinical testing for human use.
33910954
(J Virol)
PMID
33910954
Date of Publishing: 2021 Apr 28
Title Inhibitors of Coronavirus 3CL Proteases Protect Cells from Protease-Mediated Cytotoxicity
Author(s) nameResnick SJ, Iketani S et al.
Journal J Virol
Impact factor
4.16
Citation count: 1
Date of Entry 2021 Aug 10


Antiviral activity of Naringenin against SARS-CoV-2 250 and 62.5 micromolar concentrations of Naringenin were very effective in protecting cells from SARS-CoV-2 infection.
33096221
(Pharmacol Res)
PMID
33096221
Date of Publishing: 2020 Oct 20
Title Naringenin is a powerful inhibitor of SARS-CoV-2 infection in vitro
Author(s) nameClementi N, Scagnolari C et al.
Journal Pharmacol Res
Impact factor
5.78
Citation count: 2


On comparing cytokine levels in auranofin and DMSO-treated cells at 24 and 48 h, SARS-CoV-2-induced cytokines was found in significantly lower levels in auranofin treated cells.
32442105
(Virology)
PMID
32442105
Date of Publishing: 2020 Aug
Title The FDA-approved gold drug auranofin inhibits novel coronavirus (SARS-COV-2) replication and attenuates inflammation in human cells
Author(s) nameRothan HA, Stone S et al.
Journal Virology
Impact factor
2.819
Citation count: 20


Compound 13b inhibits SARS-CoV-2 replication in human Calu-3 lung cells. The hydrophobic and bulky Boc group is necessary to cross the cellular membrane https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7164518/figure/F1/
32198291
(Science)
PMID
32198291
Date of Publishing: 2020 Apr 24
Title Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved -ketoamide inhibitors
Author(s) nameZhang L, Lin D et al.
Journal Science
Impact factor
20.57
Citation count: 479


Compound 13b inhibits SARS-CoV-2 replication in human Calu-3 lung cells. The hydrophobic and bulky Boc group is necessary to cross the cellular membrane https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7164518/figure/F1/
32198291
(Science)
PMID
32198291
Date of Publishing: 2020 Apr 24
Title Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved -ketoamide inhibitors
Author(s) nameZhang L, Lin D et al.
Journal Science
Impact factor
20.57
Citation count: 479